Haemonetics Corporation Forecast, price target & analysts
Haemonetics Corporation Target price 2025 - Analyst rating & recommendation
Haemonetics Corporation Classifications & Recommendation:
Haemonetics Corporation Price Target
| Target Price | $94.35 |
| Price | $53.98 |
| Potential |
74.79%
register free of charge
|
| Number of Estimates | 12 |
|
12 Analysts have issued a price target Haemonetics Corporation 2026 .
The average Haemonetics Corporation target price is $94.35.
This is
74.79%
register free of charge
$113.40
110.08%
register free of charge
$68.68
27.23%
register free of charge
|
|
| A rating was issued by 15 analysts: 13 Analysts recommend Haemonetics Corporation to buy, 1 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Haemonetics Corporation stock has an average upside potential 2026 of
74.79%
register free of charge
|
Sales and Margin forecast 2026, 2027 & 2028
| Mar '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 1.36 | 1.32 |
| 3.95% | 2.78% | |
| EBITDA Margin | 21.57% | 33.35% |
| 15.12% | 54.62% | |
| Net Margin | 12.32% | 17.91% |
| 37.21% | 45.35% |
12 Analysts have issued a sales forecast Haemonetics Corporation 2026 . The average Haemonetics Corporation sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Haemonetics Corporation EBITDA forecast 2026. The average Haemonetics Corporation EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
12 Haemonetics Corporation Analysts have issued a net profit forecast 2026. The average Haemonetics Corporation net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028
| Mar '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 3.31 | 4.91 |
| 44.54% | 48.34% | |
| P/E | 10.98 | |
| EV/Sales | 2.66 |
12 Analysts have issued a Haemonetics Corporation forecast for earnings per share. The average Haemonetics Corporation EPS is
This results in the following potential growth metrics and future valuations:
Haemonetics Corporation...
Current Haemonetics Corporation Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Raymond James |
Locked
➜
Locked
|
Locked | Aug 11 2025 |
| Mizuho |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| Barrington Research |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
| Barrington Research |
Locked
➜
Locked
|
Locked | Jul 11 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Jul 09 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Raymond James:
Locked
➜
Locked
|
Aug 11 2025 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Aug 08 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 08 2025 |
|
Locked
Barrington Research:
Locked
➜
Locked
|
Aug 08 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Aug 07 2025 |
|
Locked
Barrington Research:
Locked
➜
Locked
|
Jul 11 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Jul 09 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
